Development and Usability Testing of a Progressive WebApp for Women With Heart Disease (at heart)
調査の概要
詳細な説明
Phase 3 (Study 3): Pilot Randomized Controlled Trial of the at heart (formerly called HEARTPA♀N) Intervention.
The at heart intervention is the first of its kind; there are no previous trials of the efficacy of such an intervention to decrease pain and improve HRQoL in women with heart disease. The investigators will undertake a process and preliminary effect evaluation of the intervention for women with heart disease, as guided by the MRC framework. The primary objective is to determine the feasibility of implementing an RCT of the intervention. A process evaluation will be conducted to examine: 1) the feasibility of randomization, recruitment and retention, 2) acceptability and barriers to implementing the intervention (including the symptom triage algorithms), and 3) the extent of engagement with the intervention. The investigators will also undertake a preliminary efficacy evaluation of the primary outcomes. Based on the investigator's theorized mechanism of change, they hypothesize that the intervention will reduce pain and improve HRQoL (primary outcomes). The investigators will assess the variability and sensitivity to change for both outcomes. Prior to conducting a full scale RCT of a complex intervention, such as at heart, the MRC recommends that a pilot trial be performed. Results from this pilot trial will inform the success of a future RCT in three ways: 1) help determine sample size calculation for the full-scale trial, 2) test procedures (recruitment, randomization, follow-up), which will make up the design of the full-scale trial, and 3) test feasibility of implementing the intervention, particularly by estimating rates of recruitment and retention. Triage algorithms and self-management interventions will be developed using a strong theoretical framework, informed by needs assessments and a comprehensive integrated mixed methods systematic review, with preliminary acceptability and usability testing by end-users. The investigators anticipate minimal risk to safety but will track adverse events using the Adverse Event Form. Moreover, latest WebApp technologies have been integrated through the use of a Chatbot named 'Holly'.
研究の種類
入学 (予想される)
段階
- 適用できない
連絡先と場所
研究連絡先
- 名前：Monica Parry, PhD
- 電話番号：416.946-3561
- メール：monica.parry@utoronto.ca
研究連絡先のバックアップ
- 名前：Myra Leyden, MA
- 電話番号：416.978.1327
- メール：myra.leyden@utoronto.ca
研究場所
-
-
Ontario
-
Toronto、Ontario、カナダ、M5T 1P8
- 募集
- Monica Parry
-
コンタクト：
- Monica Parry, PhD
- 電話番号：416.946.3561
- メール：monica.parry@utoronto.ca
-
コンタクト：
- Arland O'Hara, BA
- メール：arland.ohara@utoronto.ca
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- women greater than 18 years of age with obstructive and non-obstructive CAD pain, post PCI/cardiac surgery pain lasting greater than 3 months
- women will be required to speak and read English
Exclusion Criteria:
- severe cognitive impairment assessed using the Six-Item Screener
- major co-morbid medical or psychiatric illness that could preclude their ability to participate
研究計画
研究はどのように設計されていますか？
デザインの詳細
- 主な目的：支持療法
- 割り当て：ランダム化
- 介入モデル：並列代入
- マスキング：独身
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
介入なし：Control
Participants allocated to the control group will receive the usual care and supports provided to women with cardiac pain, including usual clinic appointments and follow-up.
|
|
|
実験的：Treatment
Participants allocated to the treatment group will also learn how to use the progressive WebApp intervention.
The intervention will be delivered on restricted password-protected applications that will permit tracking of adherence (number of logins to app and website using Google Analytics).
Participants will be encouraged to log-in regularly to the progressive WebApp (via automated alerts) over the 3-month period to complete a Heart and/or Wellness Check.
A Chatbot named 'Holly' will assist women with log-in and maintaining health and wellness.
Participants will be directed to the PC for technical problems.
|
An integrated smartphone and web-based intervention (at heart) to provide evidence-informed symptom triage and self-management support to reduce pain and increase health-related quality of life (HRQoL) in women with heart disease.
The intervention for participants randomized to the treatment group will consist of regular use of a progressive WebApp that is managed by a Chatbot named 'Holly', in addition to usual care, for a period of 3 months.
|
この研究は何を測定していますか？
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Feasibility (recruitment, retention, engagement)
時間枠：3 months
|
A process evaluation will be used to assess the feasibility of the implementation of the intervention.
The PC will track any issues or difficulties encountered during trial implementation, such as problems using the app.
Engagement will be assessed using Google Analytics, which will track patterns of app and website usage.
Engagement with the app diary will be defined as 100% with daily entries for 3 months.
Engagement with goal setting will be defined as 100% when 12 goals are identified over the 3-month period.
Criteria for implementation success: recruitment rates > 70%, retention > 85%, minimal technical difficulties reported by < 10%, engagement > 80%, and minimal missed responses.
Prevalence of refusal, retention, engagement and technical difficulties reported will be calculated with their 95% confidence intervals.
|
3 months
|
|
Feasibility (acceptability, satisfaction)
時間枠：3 months
|
The investigators will also assess acceptability and satisfaction in all participants in the intervention group using a modified Acceptability e-Scale (AES).
The modified AES includes 9 items, each with a 5-point Likert response.
Higher scores represent better acceptability/satisfaction.
Responses are summed and averaged.
Criteria for implementation success: AES mean summary score > 4.
|
3 months
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Pain (Brief Pain Inventory)
時間枠：3 months
|
A preliminary efficacy evaluation will also be undertaken focusing on the outcomes of pain.
Pain will be measured using the Brief Pain Inventory-Short Form (BPI-SF), which rates pain severity and the degree to which pain interferes with mood, sleep, and other physical activities such as work, social activity and relations with others.
We will investigate the variability and sensitivity to change for pain (T2-T1).
We will calculate the number of participants who report clinically meaningful decreases in pain, which has been defined for the BPI-SF as a two-point difference in worst pain.
Variability will be estimated using the mean/median scores and standard deviation, in each group separately, at pre and post-test.
|
3 months
|
|
Health-related quality of life (HRQOL)
時間枠：3 months
|
A preliminary efficacy evaluation will also be undertaken focusing on the outcomes of HRQOL.
HRQOL will be measured using the SF-36v2TM, which contains 36 items and yields a score for each of the 8 domains of health: physical functioning, role limitations due to physical health (role-physical), bodily pain, general health perceptions, vitality, social functioning, role limitations due to emotional problems (role emotional), and mental health.
We will investigate the variability and sensitivity to change for HRQOL (T2-T1).
Sensitivity to change will be assessed by determining the number of participants who had a clinically meaningful increase in HRQOL: ≥ 15 points in physical functioning, general health and mental health; ≥ 16.7 in role emotional functioning; ≥ 18.5 points in role physical functioning and vitality; ≥ 20 points in bodily pain; and ≥ 25 points in social functioning.
|
3 months
|
協力者と研究者
スポンサー
捜査官
- 主任研究者：Monica Parry, PhD、University of Toronto
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始 (予想される)
一次修了 (予想される)
研究の完了 (予想される)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。